1 July 2025 in Journal of Pharmacy & Pharmacognosy Research
Context: Cholestasis is marked by a disturbance in bile flow from the liver and potentially progresses to cirrhosis. Hepatic transplantation is the mainstay of therapy in hepatic cirrhosis, which is a high-cost, time-consuming, and complex procedure. Increasing evidence regarding the major role of gut microbiota in bile acid metabolism has prompted the effort to study probiotics as a potential alternative therapeutic strategy in chronic liver disease. Aims: To explore the effect of probiotic administration on Bifidobacterium, as part of the gut microbiota, and bilirubin levels in mice with cholestasis after biliary duct ligation who received standard ursodeoxycholic acid (UDCA) therapy. Methods: Thirty-five male Sprague Dawley rats were randomly assigned into seven groups: Sham-operated rats as healthy controls, cholestatic rats as negative control, UDCA only, probiotics only, and three groups received UDCA-probiotics on a stratified dose for 21 days. The bile duct ligation (BDL) procedure was used to induce cholestasis. Biochemical analyses were conducted for direct and total bilirubin levels, while Bifidobacterium DNA quantification was assessed with PCR. Results: BDL induces cholestasis, marked by a significant increase in direct and total bilirubin levels. The combination of UDCA-probiotics increased the amount of Bifidobacterium, with the highest dose of probiotics showing the highest amount, and the results were comparable among the other groups. The lowest direct and total bilirubin levels were found in the groups with the highest probiotics dose and UDCA combination. Conclusions: UDCA and probiotic combination significantly improved the amount of Bifidobacterium and bilirubin levels in cholestatic rats.